ICON plc

  • Market Cap: Small Cap
  • Industry: Miscellaneous
  • ISIN: IE0005711209
USD
185.77
2.63 (1.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ICON plc stock-summary
stock-summary
ICON plc
Miscellaneous
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Company Coordinates stock-summary
Company Details
South County Business Park, Dublin 18 , DUBLIN None : 00000
stock-summary
Tel: 353 1 29120001 888 3817923
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 144 Schemes (41.11%)

Foreign Institutions

Held by 272 Foreign Institutions (29.33%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Ciaran Murray
Non-Executive Chairman of the Board
Dr. Stephen Cutler
Chief Executive Officer, Director
Mr. Ronan Murphy
Lead Independent Director
Prof. Hugh Brady
Independent Director
Dr. John Climax
Independent Director
Ms. Joan Garahy
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2,017 Million
(Quarterly Results - Jun 2025)
Net Profit:
183 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 13,829 Million (Small Cap)

stock-summary
P/E

12.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.32

stock-summary
Return on Equity

9.88%

stock-summary
Price to Book

1.45